BRIACELL THERAPEUTICS CORP. Comprehensive Income
BRIACELL THERAPEUTICS CORP. (BCTX) reported Comprehensive Income of -$4.90 million for the 3-month period ending 2023-04-30, per its 10-Q filed 2023-06-14.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2023-06-14
- BRIACELL THERAPEUTICS CORP. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-04-30 was -$4.90M.
- BRIACELL THERAPEUTICS CORP. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-01-31 was -$11.88M, a 206.46% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-04-30 was -$10.02M.
- BRIACELL THERAPEUTICS CORP. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-01-31 was $11.16M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month |
|---|---|---|---|
| 2023-04-30 | -$4.90M 10-Q · filed 2023-06-14 | -$16.78M derived: sum of 2 quarters · filed 2023-06-14 | -$17.88M 10-Q · filed 2023-06-14 |
| 2023-01-31 | -$11.88M 10-Q · filed 2023-03-16 | -$12.99M 10-Q · filed 2023-03-16 | |
| 2022-04-30 | -$10.02M 10-Q · filed 2023-06-14 | $1.14M derived: sum of 2 quarters · filed 2023-06-14 | -$26.39M 10-Q · filed 2023-06-14 |
| 2022-01-31 | $11.16M 10-Q · filed 2023-03-16 | -$16.37M 10-Q · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |